Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Information, Expiry & Status of Health Canada Patents covering Imatinib Mesilate.

Client Email

Product

Imatinib Mesilate
HEALTH CANADA PATENTS

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

Bora Pharmaceuticals- Making success more certain.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

Axplora- The partner of choice for complex APIs.

Contact Supplier

Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

Contact Supplier

Imatinib Mesilate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

100 API Suppliers, 35 USDMF, 20 CEP/COS, 8 JDMF, 16 EU WC, 30 KDMF, 21 NDC API, 63 Listed Suppliers, $ API Reference Price

100 API Suppliers
35 USDMF
20 CEP/COS
8 JDMF
16 EU WC
30 KDMF
21 NDC API
63 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

23 Drugs in Development

23 Drugs in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

API Reference Price
API Exports
API Imports
FDF Exports
FDF Imports

INTERMEDIATES

44 API Suppliers

44 API Suppliers

FINISHED DOSAGE FORMULATIONS

497 FDF Dossiers, 32 FDA Orange Book, 101 Europe, 20 Canada, 280 Australia, 17 South Africa, 47 Listed Dossiers

497 FDF Dossiers
32 FDA Orange Book
101 Europe
20 Canada
280 Australia
17 South Africa
47 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 100MG BASE, TABLET;ORAL - EQ 400MG BASE

TABLET;ORAL - EQ 100MG BASE
TABLET;ORAL - EQ 400MG BASE

RELATED EXCIPIENT COMPANIES

1 Minakem, 1 Rochem International Inc, 14 SPI Pharma, 2 Seqens, 10 DKSH, 2 Jai Radhe Sales, 6 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 10 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 3 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 17 BASF, 1 Clariant, 10 Corel Pharma Chem, 5 DFE Pharma, 1 Finar, 9 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 7 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 33 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 14 Microlex e.U, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 4 Novo Excipients, 3 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 13 Roquette, 6 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

80 Fillers, Diluents & Binders, 52 Coating Systems & Additives, 39 Direct Compression, 30 Disintegrants & Superdisintegrants, 29 Controlled & Modified Release, 22 Thickeners and Stabilizers, 22 Granulation, 20 Lubricants & Glidants, 16 Chewable & Orodispersible Aids, 14 Co-Processed Excipients, 13 Film Formers & Plasticizers, 13 Taste Masking, 13 Solubilizers, 10 Topical, 10 Parenteral, 6 API Stability Enhancers, 5 Emulsifying Agents, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Coloring Agents, 3 Rheology Modifiers, 1 Surfactant & Foaming Agents

80 Fillers, Diluents & Binders
52 Coating Systems & Additives
39 Direct Compression
30 Disintegrants & Superdisintegrants
29 Controlled & Modified Release
22 Thickeners and Stabilizers
22 Granulation
20 Lubricants & Glidants
16 Chewable & Orodispersible Aids
14 Co-Processed Excipients
13 Film Formers & Plasticizers
13 Taste Masking
13 Solubilizers
10 Topical
10 Parenteral
6 API Stability Enhancers
5 Emulsifying Agents
5 Empty Capsules
4 Vegetarian Capsules
4 Coloring Agents
3 Rheology Modifiers
1 Surfactant & Foaming Agents

DIGITAL CONTENT

8 DATA COMPILATION #PharmaFlow, 150 NEWS #PharmaBuzz

8 DATA COMPILATION #PharmaFlow
150 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 43 Finished Drug Prices, 10 Annual Reports

2 US Medicaid Prescriptions
43 Finished Drug Prices
10 Annual Reports

MARKET PLACE

19 APIs, 15 FDF Dossiers

19 APIs
15 FDF Dossiers

PATENTS & EXCLUSIVITIES

8 Health Canada Patents

8 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 6 Others

1 EDQM
6 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 959 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

8 All

01 2Gowling WLG (Canada) LLP

02 6Gowlings

filter Patent Reset all filters

8 All

01 22093203

02 22483199

03 42622808

filter Product Reset all filters

8 All

01 8Imatinib Mesylate

filter Dosage Reset all filters

8 All

01 2Capsule

02 6Tablet

filter Exp Date Reset all filters

8 All

01 22013-04-01

02 42018-07-16

03 22023-04-22

Product Main Page

01

Gowlings

Imatinib Mesylate

Luxepack

Not Confirmed

Gowlings

Canada

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2013-04-01

Date Granted : 2002-11-26

Imatinib Mesylate

Brand Name : GLEEVEC

Patent Number : 2093203

Filing Date : 1993-04-01

Strength per Unit : 400 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2013-04-01

Date Granted : 2002-11-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Gowlings

Imatinib Mesylate

Luxepack

Not Confirmed

Gowlings

Canada

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2013-04-01

Date Granted : 2002-11-26

Imatinib Mesylate

Brand Name : GLEEVEC

Patent Number : 2093203

Filing Date : 1993-04-01

Strength per Unit : 100 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2013-04-01

Date Granted : 2002-11-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Gowlings

Imatinib Mesylate

Luxepack

Not Confirmed

Gowlings

Canada

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2018-07-16

Date Granted : 2011-03-01

Imatinib Mesylate

Brand Name : GLEEVEC

Patent Number : 2622808

Filing Date : 1998-07-16

Strength per Unit : 400 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2018-07-16

Date Granted : 2011-03-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Gowlings

Imatinib Mesylate

Luxepack

Not Confirmed

Gowlings

Canada

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2018-07-16

Date Granted : 2011-03-01

Imatinib Mesylate

Brand Name : GLEEVEC

Patent Number : 2622808

Filing Date : 1998-07-16

Strength per Unit : 100 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2018-07-16

Date Granted : 2011-03-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Gowlings

Imatinib Mesylate

Luxepack

Not Confirmed

Gowlings

Canada

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2018-07-16

Date Granted : 2011-03-01

Imatinib Mesylate

Brand Name : GLEEVEC

Patent Number : 2622808

Filing Date : 1998-07-16

Strength per Unit : 50 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2018-07-16

Date Granted : 2011-03-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Gowlings

Imatinib Mesylate

Luxepack

Not Confirmed

Gowlings

Canada

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2018-07-16

Date Granted : 2011-03-01

Imatinib Mesylate

Brand Name : GLEEVEC

Patent Number : 2622808

Filing Date : 1998-07-16

Strength per Unit : 100 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2018-07-16

Date Granted : 2011-03-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

Gowling WLG (Canada) LLP

Imatinib Mesylate

Luxepack

Not Confirmed

Gowling WLG (Canada) LLP

Canada

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2023-04-22

Date Granted : 2010-08-17

Imatinib Mesylate

Brand Name : GLEEVEC

Patent Number : 2483199

Filing Date : 2003-04-22

Strength per Unit : 400 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2023-04-22

Date Granted : 2010-08-17

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

Gowling WLG (Canada) LLP

Imatinib Mesylate

Luxepack

Not Confirmed

Gowling WLG (Canada) LLP

Canada

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2023-04-22

Date Granted : 2010-08-17

Imatinib Mesylate

Brand Name : GLEEVEC

Patent Number : 2483199

Filing Date : 2003-04-22

Strength per Unit : 100 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2023-04-22

Date Granted : 2010-08-17

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?